Our services span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.
Site and patient identification, enrolment and engagement.
Integrated services that cover planning, management, execution and analysis.
ICON provides its full range of clinical, consulting and commercial services across several sectors.
The new EU medical and in vitro diagnostic device regulations go into effect at the start of 2020. Are you ready.
Strategies and recommendations to achieve optimal market access.
We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.
ICON has conducted hundreds of clinical studies in both solid and haematological tumours, including experience with CAR-T therapies.
ICON has recently led the development of 14 vaccines resulting in FDA/EMA approvals.
We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.
Using data to design, simulate, and analyse adaptive clinical trials with ease.
Connecting patients with the right trial in the right location.
BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.
Remote monitoring and leveraging wearable devices and sensors in clinical trials.
Reduce post market study costs with Real World Data.
ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.
27 - 28 January, 2020
Visit the Webinar Channel
Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.
We are committed to exceeding the quality standards demanded by our clients, patients and regulatory authorities.
Partners Making a Difference.
1:00:08
In collaboration with DIA and CitiusTech, Inc.
50:02
Our experts explore how manufacturers can successfully implement the FDA's guidance on Payer Communications and integrate these new communication channels with payers
57:23
The emergence and rise of gene and cell therapies has the potential to significantly change the way we manage and treat disease. While payers recognize that gene and cell therapies are likely to be the next big step in the evolution of medicine, the
31:37
In this webinar, we review the accumulating evidence to support measurement equivalence of instruments when migrated to ePRO. We review meta analyses of published quantitative equivalence studies, and a newly published meta synthesis of unpublished c
48:36
1:00:09
This webinar explores: the evolution of health technology assessment in the US and possibilities for the future; opinions of manufacturers and US payer stakeholders on the role of ICER in the US healthcare system; ICER methodologies and approaches
1:02:20
